Parasiticides
Parasiticides
Search
Technologies
We are expanding our global network of technology partners. Learn more about partnering with us.
More Health Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Mental Health disorders
Mental Health disorders
Corporate Compliance Program
Our E&C Program conforms with the principles and recommendations published in guides from various Federal agencies and industry related organizations
Our People, Our Culture
Our People, Our Culture
We’re All In
We’re All In
Vaccines
Vaccines
Animal Health Partnering
Animal Health Partnering
Partnering with Boehringer Ingelheim
Information on partnering with Boehringer Ingelheim including how the company enables new science, partnering interests and key facts on the R&D pipeline.
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Metabolic Diseases
CardioMetabolic Disease Research
Animal Health Partnering Interests
Learn about our Partnering Interests and how we can work together to advance innovation in animal health
Oncology & Cancer Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Citizen Petition
Citizen Petition
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies
Black innovators contribution to health & wellness throughout the years
Read about the many contributions Black innovators have made throughout history and how they continue to shape scientific discoveries today.
Transboundary and Emerging Diseases | Boehringer Ingelheim US
Click here to find out more on how Boehringer Ingelheim fights transboundary and emerging diseases through cutting-edge technologies.
History
History
Swine Vaccine Combo for Two Diseases | Boehringer Ingelheim US
Click here to read more on the launch of the Boehringer Ingelheim innovative vaccine combination, protecting US swine from two viruses in one shot.
Human Health
Human Health
Partnering Culture
BI's long-term research and investment focus means we can work together to realize their ideas by fully committing to lasting relationships.
Partnering in Retinal Health
Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Boehringer Ingelheim Office Hours Video 2023
Video providing an overview of Boehringer Ingelheim’s Office Hours program and how its mentoring and access to expertise can help early-stage companies advance their science.
Meet our Team
Meet Our Team